Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

165 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-06-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the global incidence of the endometrial changes in postmenopausal women receiving Anastrozole for the adjuvant treatment of hormone receptors positive breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy

NCT00542594

Breast Cancer

TERMINATED

Breast Cancer Tumor Care Observational Programme

NCT00660244

Post Menopausal Arthralgia

COMPLETED

3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer

NCT00300508

Breast Neoplasms

COMPLETED PHASE3

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

NCT00357110

Breast Cancer

COMPLETED PHASE2

Secondary Adjuvant Long Term Study With Arimidex

NCT00295620

Breast Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of Informed Consent
* Resectable breast cancer patients, with histological confirmation
* Patients eligible to receive hormonal adjuvant treatment with Anastrozole
* They are allowed patients treated with adjuvant chemo or radiotherapy concurrently
* Patients previously treated with Tamoxifen that had to withdraw treatment due to other reason than endometrial changes are allowed
* Postmenopausal patients(aged 50 years or over/ without menses in the last months/ FSH level \>40UI/L / women under 50 years with FSH levels\>40UI/L).
* Women showing progesterone and/or estrogen receptors positive.

Exclusion Criteria

* Patients with evidence of metastatic disease
* Patients unsuitable to receive the medication according the Anastrozole label
* Patients not giving their Informed Consent

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No